Chimeric antigen receptor-modified CD34+ stem cell, and preparation method therefor and use thereof
By constructing chimeric antigen receptors to modify CD34+ stem cells and utilizing CAR technology targeting VCAM-1 and VEGFA, the problem of insufficient targeting and repair capabilities of CD34+ stem cells at cardiovascular disease injury sites has been solved, achieving efficient endothelial cell repair and proliferation, and providing a minimally invasive treatment option for cardiovascular diseases.
Patent Information
- Application Number
- PCT/CN2026/095951
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-09
- Publication Date
- 2026-11-12
AI Technical Summary
Existing technologies are insufficient to effectively improve the targeting and repair capabilities of CD34+ stem cells at sites of cardiovascular disease injury, especially in terms of local survival and functional enhancement.
By constructing a chimeric antigen receptor (CAR) to modify CD34+ stem cells, using a single-chain antibody (scFv) targeting VCAM-1 and VEGFA as intracellular domains, a CAR overexpression plasmid was constructed, and then transduced via a lentiviral vector to prepare chimeric antigen receptor-modified CD34+ stem cells, endowing them with targeting and the ability to promote endothelial cell repair.
This study achieved targeted enhancement of CD34+ stem cells in cardiovascular diseases, improved their migration, differentiation and proliferation capabilities at the site of injury, promoted endothelial cell repair and exosome secretion, and provided a minimally invasive treatment option for cardiovascular diseases.
Smart Images

Figure PCTCN2026095951-FTAPPB-I100001 
Figure PCTCN2026095951-FTAPPB-I100002 
Figure PCTCN2026095951-FTAPPB-I100003
Abstract
Description
Chimeric antigen receptor-modified CD34+ stem cells, their preparation methods and applications Technical Field
[0001] This application relates to the field of stem cell therapy technology, specifically to a chimeric antigen receptor-modified CD34+ stem cell, its preparation method, and its application. Background Technology
[0002] Circulating CD34+ stem cells (PCs) have been shown to be mobilized from bone marrow and play a role in repair and angiogenesis in cardiovascular disease. They can directly differentiate into endothelial cells (ECs) and release bioactive molecules, such as exosomes and PPAR agonists, to enhance EC activity. Studies have found that injection of CD34+ PCs can improve EC growth on grafts. To address these challenges, current research has explored methods for recruiting CD34+ stem cells at lesion sites, such as using custom scaffolds designed to enhance CD34+ cell survival at the injury site. Therefore, the focus of research is on increasing the number and function of CD34+ stem cells in the lesion site and guiding them to homing (targeting) to the injury site.
[0003] Chimeric antigen receptor T cells (CAR-T) and macrophages (CAR-M) have been widely used in targeted cancer therapy and have shown significant efficacy. Studies have utilized genetically engineered CAR hematopoietic stem cells (CAR-HPSCs) to generate allogeneic hematopoietic stem cell engineered iNKT (AlloHSC-iNKT) cells, which effectively target tumor cells. These research results indicate that the use of CAR-based technologies in stem cell therapy may be feasible and holds great promise for the future. Many cardiovascular diseases are characterized by high expression of inflammatory factors such as VCAM-1 at the site of injury. Meanwhile, VEGFA has the function of promoting angiogenesis and endothelial cell proliferation and repair, and can stimulate stem cell differentiation into endothelial cells. Summary of the Invention
[0004] This application provides a method for preparing chimeric antigen receptor-modified CD34+ stem cells, comprising the following steps: Step 1, rinsing bone marrow fluid from the femoral bone marrow of C57BL / 6J mice and centrifuging to purify C57BL / 6J mouse femoral bone marrow mononuclear cells; Step 2, separating and purifying the purified C57BL / 6J mouse femoral bone marrow mononuclear cells using magnetic bead separation to obtain CD34+ cells, culturing and proliferating them for passage to obtain primary CD34+ stem cells of C57BL / 6J mice; Step 3, constructing a CAR overexpression plasmid; Step 4, using the CAR overexpression plasmid and lentivirus to package a CAR overexpression lentiviral vector; Step 5, co-culturing the CAR overexpression lentiviral vector with primary CD34+ stem cells of C57BL / 6J mice to obtain chimeric antigen receptor-modified CD34+ stem cells.
[0005] This application also provides a chimeric antigen receptor-modified CD34+ stem cell, prepared using the above method.
[0006] This application also provides the use of chimeric antigen receptor-modified CD34+ stem cells in the preparation of products for the treatment of cardiovascular endothelial injury. Attached Figure Description
[0007] Figure 1 is a flowchart of the isolation of CD34+PC from the bone marrow of C57BL / 6J mice according to one or more embodiments.
[0008] Figure 2 is an immunofluorescence staining image of CD34+ stem cells according to one or more embodiments.
[0009] Figure 3 is a flow cytometry staining diagram of CD34+ stem cells according to one or more embodiments.
[0010] Figure 4 is a schematic diagram of a CAR structure according to one or more embodiments.
[0011] Figure 5 shows CAR overexpression plasmids and CAR overexpression lentiviral vectors according to one or more embodiments.
[0012] Figure 6 illustrates the construction and purification of lentiviral CAR vectors according to one or more embodiments.
[0013] Figure 7 shows the expression levels of anti-VCAM-1scFv in CD34+ stem cells among different groups according to one or more embodiments.
[0014] Figure 8 shows the expression stability of CD34+ stem cells against VCAM-1scFv in different groups according to one or more embodiments.
[0015] Figure 9 shows the expression levels of VEGFA among different groups according to one or more implementation methods.
[0016] Figure 10 shows the in vitro proliferation capacity of CD34+ stem cells among different groups according to one or more embodiments.
[0017] Figure 11 shows the detection of CD34+ stem cell differentiation capacity among different groups according to one or more embodiments. Detailed Implementation
[0018] This application provides a method for preparing chimeric antigen receptor-modified CD34+ stem cells, comprising the following steps: Step 1, rinsing bone marrow fluid from the femoral bone marrow of C57BL / 6J mice and centrifuging to purify and obtain purified C57BL / 6J mouse femoral bone marrow mononuclear cells; Step 2, separating and purifying the purified C57BL / 6J mouse femoral bone marrow mononuclear cells using a magnetic bead separation method to obtain CD34+ cells, culturing and proliferating them for passage to obtain primary CD34+ stem cells of C57BL / 6J mice; Step 3, constructing a CAR overexpression plasmid; Step 4, using the CAR overexpression plasmid and lentivirus to package a CAR overexpression lentiviral vector; Step 5, co-culturing the CAR overexpression lentiviral vector with the primary CD34+ stem cells of C57BL / 6J mice to obtain chimeric antigen receptor-modified CD34+ stem cells.
[0019] In some embodiments, step 1 includes: taking the femur of a C57BL / 6J mouse, washing out the bone marrow cell suspension with M199 culture medium and filtering it through a 70μm sieve to obtain the filtered bone marrow suspension.
[0020] In some embodiments, step 1 further includes: centrifuging the filtered bone marrow suspension using a centrifuge at 37°C, 300 g / min, for 10 min; resuspending the cells and adding them above the lymphocyte separation medium; centrifuging at 18-20°C, 2000 r / min, for 30 min; taking the intermediate layer cells; adding them to PBS buffer; centrifuging at 300 g / min, for 5 min; and resuspending to obtain purified C57BL / 6J mouse femoral bone marrow mononuclear cells.
[0021] In some embodiments, step 2 includes: mixing the purified C57BL / 6J mouse femoral bone marrow mononuclear cells with CD34+ magnetic beads and incubating at room temperature for 30 min to obtain a mixture.
[0022] In some embodiments, the magnetic beads are MACS CD34 MicroBeads.
[0023] In some embodiments, step 2 further includes:
[0024] The mixture was sorted using a MACS magnetic sorting system to obtain a cell suspension, which was then transferred to a sorting tube. The sorted cells were washed multiple times to obtain enriched CD34+ stem cells.
[0025] In some embodiments, step 2 further includes:
[0026] The enriched CD34+ stem cells were resuspended in EGM-2 medium and the cell density was adjusted to 1×106 cells / ml. The cell suspension was then transferred to a 6-well plate pre-coated with human plasma fibrin and cultured in a cell culture incubator at 37°C and 5% CO2. The medium was changed for the first time after 3 days, and the morphology and growth of the cells were observed.
[0027] In some embodiments, after obtaining the primary CD34+ stem cells of C57BL / 6J mice, it is also necessary to perform immunophenotypic identification on the primary CD34+ stem cells of C57BL / 6J mice.
[0028] In some embodiments, the immunophenotyping identification is performed using flow cytometry and immunofluorescence, and the antibodies used are CD34 flow cytometry antibody and CD34 antibody, respectively.
[0029] In some embodiments, step 3 includes:
[0030] The scFv target VCAM-1, with CD28 as the hinge region and VEGFA as the intracellular domain. The VCAM-1 single-chain antibody and VEGFA gene were constructed into the PGMLV-EF1a-hinge_TM(CD28) vector to obtain the CAR overexpression plasmid.
[0031] In some embodiments, the nucleotide sequence of the scFv targeting VCAM-1 is shown in SEQ ID No: 1, and the gene base sequence of VEGFA is shown in SEQ ID No: 2.
[0032] In some embodiments, in step 4, the lentivirus is derived from the supernatant of HEK293T cells.
[0033] In some embodiments, in step 4, the lentivirus packaging uses a kit to co-transfect 10 μL of the CAR overexpression plasmid with 10 μL of the lentivirus mixture and 60 μL of HGTransgene™ reagent for 2 days to obtain a virus concentrate, which is the CAR overexpression lentivirus vector.
[0034] In some embodiments, in step 5, the CAR-overexpressing lentiviral vector is diluted with an MOI of 50 and 1×10⁻⁶. 5 Primary CD34+ stem cells from C57BL / 6J mice were co-cultured for 16 hours to obtain chimeric antigen receptor-modified CD34+ stem cells. The culture medium used for co-culture was EGM-2 cell culture medium + 0.5 μg / mL puromycin.
[0035] This application provides a method for preparing chimeric antigen receptor-modified CD34+ stem cells, which are prepared using the above method.
[0036] This application also provides the use of chimeric antigen receptor-modified CD34+ stem cells in the preparation of products for the treatment of cardiovascular endothelial injury.
[0037] The chimeric antigen receptor-modified CD34+ stem cells prepared in this application can target the scFV of vascular cell adhesion molecule-1 (VCAM-1) and secrete vascular endothelial growth factor A (VEGFA). This not only targets common cardiovascular diseases but also increases the ability of CD34+ stem cells to proliferate, migrate, differentiate into endothelial cells, and secrete exosomes to repair vascular damage.
[0038] This application is the first to apply chimeric antigen receptor technology to the treatment of cardiovascular diseases, providing a promising prospect for its minimally invasive and non-invasive treatment.
[0039] To make the technical means, creative features, objectives and effects of this application easy to understand, the following embodiments, in conjunction with the accompanying drawings, specifically illustrate the chimeric antigen receptor-modified CD34+ stem cells of this application, their preparation methods and applications.
[0040] Example
[0041] This embodiment provides a chimeric antigen receptor-modified CD34+ stem cell, its preparation method, and its application.
[0042] The method for preparing chimeric antigen receptor-modified CD34+ stem cells includes the following steps:
[0043] Step 1: Bone marrow fluid was flushed out from the femoral bone marrow of C57BL / 6J mice, and purified by centrifugation to obtain purified C57BL / 6J mouse femoral bone marrow mononuclear cells, which were then cultured in a culture medium.
[0044] Step 1 includes the following sub-steps:
[0045] Step 1-1: Thoroughly disinfect the operating instruments and mice, expose the femur of C57BL / 6J mice, use a syringe to draw 2ml of M199 culture medium to rinse the bone marrow until the bone marrow cavity becomes clear; transfer the rinsed bone marrow cell suspension to a 50ml centrifuge tube with a 70μm sieve, and then add 5ml of M199 culture medium to the centrifuge tube to obtain the filtered bone marrow suspension.
[0046] Steps 1-2: Place the filtered bone marrow suspension in a preheated (37°C) high-speed centrifuge and centrifuge at 300 g / min for 10 min. After centrifugation, remove excess culture medium and resuspend the cells in 3 ml of M199 medium. Gently transfer the resuspended bone marrow cells onto a layer of lymphocyte separation medium (density 1.078) and carefully place the centrifuge. Centrifuge at 18-20°C and 2000 rpm for 30 min. After centrifugation, carefully aspirate the intermediate layer of monocytes, add 2 ml of PBS buffer, centrifuge at 300 g / min for 5 min, wash and resuspend the monocytes, adjusting the cell concentration to 1.5 x 10⁻⁶ cells / mL. 6 Cells / ml were used to obtain purified femoral bone marrow mononuclear cells from C57BL / 6J mice.
[0047] Step 2: The purified femoral bone marrow mononuclear cells of C57BL / 6J mice were separated and purified by magnetic bead separation to obtain CD34+ cells, which were then cultured, proliferated and passaged to obtain primary CD34+ stem cells of C57BL / 6J mice.
[0048] Step 2 includes the following sub-steps:
[0049] Step 2-1: Purified C57BL / 6J mouse femoral bone marrow mononuclear cells were mixed with pre-prepared CD34+ magnetic beads and incubated at room temperature for 30 min to obtain the mixture. The magnetic beads used were MACS CD34 MicroBeads.
[0050] Step 2-2: The mixture is sorted using the MACS magnetic sorting system to collect the enriched CD34+ cells, obtain a cell suspension, and transfer the cell suspension to a sorting tube. The sorted cells are washed multiple times to obtain enriched CD34+ stem cells.
[0051] Steps 2-3: Resuspend the enriched CD34+ stem cells in EGM-2 medium and adjust the cell density to 1×10⁻⁶ cells / year. 6 Cells / ml were collected, and the cell suspension was then transferred to 6-well plates pre-coated with human plasma fibrin. After washing with 3 ml of EGM-2 medium in centrifuge tubes, 1 ml of the solution was transferred to each well of the culture plate. The 6-well plates were incubated at 37°C with 5% CO2. The medium was changed for the first time after 3 days to remove suspended and dead cells. Thereafter, the medium was changed every 2 days, and cell morphology and growth were observed.
[0052] The experimental procedures for steps 1 and 2 above are shown in Figure 1.
[0053] Step 3: Immunophenotypic identification of primary CD34+ stem cells from C57BL / 6J mice. Immunophenotypic identification was performed using flow cytometry and immunofluorescence, with CD34 flow cytometry antibody and CD34 antibody used, respectively.
[0054] Step 3 includes the following sub-steps:
[0055] Step 3-1: Seed CD34+ cells onto coverslips and fix with 4% paraformaldehyde solution at room temperature for 15-20 minutes. Incubate with 0.1%-0.3% Triton X-100 solution at room temperature for 10 minutes, then block with 5%-10% BSA solution at room temperature for 30 minutes. Dilute the CD34 primary antibody to 1:100, dilute with antibody diluent, and add to the cells. Incubate at room temperature in the dark for 1 hour. Wash cells three times with PBS buffer for 5 minutes each time. Dilute the fluorescently labeled secondary antibody to 1:200 and add to the cells. Incubate at room temperature in the dark for 30-60 minutes. Wash as before. Add 1 μg / ml DAPI staining solution to the cells and incubate in the dark for 5 minutes. Wash as before. Observe the CD34 fluorescence signal of the cells under a fluorescence microscope. The flowchart for isolating CD34+ PCs from the bone marrow of C57BL / 6J mice, with a purity of approximately 96.16±1.22% (n=3), is shown in Figure 2.
[0056] Step 3-2: Take the above cells and prepare a cell suspension, then adjust the cell concentration to 1×10⁻⁶. 7 Cells / ml; at room temperature, fix with 4% paraformaldehyde solution for 10 minutes, 300 g / min for 5 minutes, discard supernatant; permeabilize with cold methanol at 4℃ for 30 minutes; 300 g / min for 5 minutes, prepare cell suspension again. Add 3 × 10⁻⁶ cells / ml to flow cytometry tubes. 5 30 μl of cells (approximately 30 μl) and 5 μl of FITC-labeled CD34 antibody were incubated at room temperature for 1 hour in the dark. The cells were then incubated at 300 g / min for 5 minutes. After washing, the cells were resuspended and stored at 4°C in the dark. Flow cytometry analysis was performed, and the results are shown in Figure 3.
[0057] Step 4, construct CAR overexpression plasmid:
[0058] The CAR structure design is shown in Figure 4. To endow CD34+ PCs with the ability to target VCAM-1 expressed in aortic lesions and secrete large amounts of VEGFA, thereby activating CD34+ cells and promoting endothelial cell repair, we designed a specialized cell called VCAM-1CAR-CD34+PC expressing VEGFA (VEGFA-VCAM-1-CAR PC). This tandem construct consists of a first-generation anti-VCAM-1 CAR construct and mouse VEGFA linked by a cleavable 2A peptide sequence.
[0059] The scFv target VCAM-1, with CD28 as the hinge region and VEGFA as the intracellular domain. The VCAM-1 single-chain antibody (anti-VCAM-1scFv) and the VEGFA gene were constructed into the PGMLV-EF1a-hinge_TM(CD28) vector to obtain the CAR overexpression plasmid.
[0060] The nucleotide sequence of the scFv targeting VCAM-1 (as shown in SEQ ID No: 1) is as follows:
[0061] The gene base sequence of VEGFA (as shown in SEQ ID No: 2) is as follows:
[0062] Step 4 includes the following sub-steps:
[0063] Step 4-1: Design and synthesize primers. Based on the target gene sequence (SEQ ID No: 1 and SEQ ID No: 2), design and synthesize primers for amplifying the target gene fragment. During amplification, EcoRI and BamHI restriction enzyme sites are added to both ends of the target gene to facilitate subsequent cloning operations.
[0064] Step 4-2: Cultivate and extract the vector plasmid. Select the bacterial culture of the PGMLV-EF1a-hinge_TM(CD28) vector and culture it overnight. The next day, take 3-5 mL of fresh culture medium for plasmid extraction. Ensure that the extracted plasmid has high purity and appropriate concentration.
[0065] Step 4-3: Take 1 μg of the extracted fresh plasmid and perform double digestion using the appropriate restriction endonuclease. The digestion system is set up as follows:
[0066] The enzyme digestion products were loaded into an agarose gel and separated by electrophoresis. After electrophoresis, the gel was observed under a UV lamp to locate the strip containing the target fragment. The gel strip containing the target fragment was cut off under UV light, taking care to avoid entraining other irrelevant fragments. The total weight of the gel strip was weighed using a balance, and the weight of the empty tube was subtracted to calculate the actual weight of the gel. Based on the weight of the gel, the gel volume was calculated proportionally (100 mg agarose gel is approximately equal to 100 μL), and then an equal volume of Binging Solution was added. The mixture was placed in a 65°C water bath for heating and dissolution, ensuring complete gel melting. During this process, the EP tube was gently shaken to accelerate the dissolution rate. After the gel was completely dissolved, DNA was recovered using a dedicated recovery reagent, following the instructions in the kit's manual, to obtain the purified target gene fragment.
[0067] Step 4-4: Transfer all the above liquid to the filter column and centrifuge at 13000 rpm for 30 seconds. Discard the liquid in the tube, add 500 μL of WA Solution to the filter column, and centrifuge again at 13000 rpm for 30 seconds. Discard the liquid in the tube, add 500 μL of Wash Solution to the filter column, and centrifuge at 13000 rpm for 30 seconds. Then, run the filter column empty for 3 minutes to ensure it is completely dry. Next, place the filter column in a new 1.5 mL EP tube and allow it to air dry at room temperature. Finally, add 35 μL of ddH2O to the filter column, let it stand for 5 minutes, and centrifuge again at 13000 rpm for 1.5 minutes to complete DNA elution. Add the dissolved DNA back to the filter column and centrifuge for 1 minute. Discard the filter column to obtain the recovered vector fragment, and determine its concentration.
[0068] Steps 4-5: Dilute the synthesized primers to a final concentration of 10 μmol / L in stock solution. Use this stock solution to perform PCR amplification with template DNA. The PCR reaction system is as follows:
[0069] Steps 4-6: Add the above PCR reaction system to a thin-walled tube, mix gently, and centrifuge briefly. Place the reaction tube in a PCR instrument, set the appropriate annealing and extension temperatures, and start PCR amplification. After PCR amplification, analyze the amplification products using agarose gel electrophoresis, and recover the target gene fragment as needed, following the steps outlined above.
[0070] Steps 4-7 involve ligating the target fragment to the vector using a seamless cloning method. First, the concentrations of the recovered vector and target fragment are determined. This is based on HieffClone... TM For the recombinant reaction system, the optimal amount of cloning vector is 0.03 pmol, and the optimal molar ratio of cloning vector to insert fragment is 1:2, meaning the optimal amount of insert fragment is 0.06 pmol. Based on the number of base pairs in the target DNA, the required DNA mass can be calculated using the following formula:
[0071] Optimal cloning vector dosage = [0.02 × number of base pairs in the cloning vector] ng (i.e., 0.03 pmol)
[0072] Optimal amount of insert fragment used = [0.04 × number of base pairs of insert fragment] ng (i.e. 0.06 pmol)
[0073] Steps 4-8 involve ligating the vector to the target fragment at 50°C for 20 minutes. The ligation reaction system is as follows:
[0074] Steps 4-9: Place competent cells on ice (4°C) to thaw naturally. After thawing, add 10 μL of the ligation product to the competent cells and continue to place the reaction tube on ice (4°C) for 30 minutes. Then, transfer the cells to a 42°C water bath for heat shock for 90 seconds. After heat shock, immediately place the tube on ice (4°C) for 2-3 minutes. Add 500 μL of antibiotic-free SOC medium to the reaction system, mix well, and incubate with shaking at 37°C and 225 rpm for 45 minutes.
[0075] Steps 4-10: Centrifuge the culture medium at 3000 rpm for 2 minutes and discard 900 μL of supernatant. Gently pipette the bottom of the tube to resuspend the cells. Spread the suspension onto a culture plate containing the appropriate antibiotic (such as ampicillin or kanamycin) using a sterile spreader to evenly distribute the cells. Finally, invert the culture plate and incubate overnight at 37°C.
[0076] Step 5: CAR overexpression lentiviral vectors were obtained by packaging CAR overexpression plasmids and lentiviruses. The lentiviruses were derived from the supernatant of HEK293T cells.
[0077] Step 5 includes the following sub-steps:
[0078] Step 5-1, 293T cell separation: One day before transfection, passage the 293T cells that have grown to the appropriate state into 10cm culture dishes at an appropriate ratio, and culture them until the cell density reaches 70%-80%, in preparation for transfection.
[0079] Step 5-2: Take a sterile 1.5mL EP tube or 15mL centrifuge tube and prepare the transfection system according to the following formula:
[0080] After mixing the transfection system, let it stand at room temperature for 15-20 minutes. After standing, add the transfection solution evenly to the culture dish to be transfected, and then place the culture dish in an incubator containing 5% CO2 for further incubation.
[0081] Add enhancing buffer: 10-12 hours after transfection, add 100× enhancing buffer evenly to promote transfection, at a rate of 120 μL / plate.
[0082] Step 5-3: 18-20 hours after transfection, carefully aspirate the cell culture medium and discard it in a waste container filled with sterile solution. Then add 12 mL of DMEM cell culture medium containing 1% serum and continue culturing.
[0083] Step 5-4: 48 hours after transfection, collect the cell supernatant into a 50 mL centrifuge tube and centrifuge at 4000g for 5 minutes at 4°C. Filter the supernatant through a 0.22 μm filter, and transfer the filtered liquid to a new centrifuge tube. Then, transfer the filtrate in batches to a concentration device and centrifuge at 3500g for 10 minutes at 4°C, discarding the lower layer (discard in a waste container). Finally, centrifuge again at 3500g for 20 minutes at 4°C; the liquid collected at the top of the filter at this point is the lentivirus concentrate.
[0084] Step 5-5: Aliquot the lentivirus concentrate and store it at -80°C.
[0085] Steps 5-6: Lentiviral packaging uses a kit to mix 10 μL of CAR overexpression plasmid with 10 μL of lentivirus mixture and HGTransgene. TM 60 μL of reagent was co-transfected for 2 days to obtain a concentrated viral solution, which was a CAR overexpression lentiviral vector.
[0086] The plasmid constructed in step 4 above and the CAR overexpression lentiviral vector packaged in step 5 above are shown in Figure 5. The experimental procedure for constructing the plasmid and CAR lentiviral vector is shown in Figure 6.
[0087] Step 6: The CAR-overexpressing lentiviral vector was co-cultured with primary CD34+ stem cells from C57BL / 6J mice to obtain chimeric antigen receptor-modified CD34+ stem cells.
[0088] In step 6, the CAR-overexpressing lentiviral vector was diluted with 1×10⁻⁶ at an MOI of 50. 5 Primary CD34+ stem cells from C57BL / 6J mice were co-cultured for 16 hours to obtain chimeric antigen receptor-modified CD34+ stem cells. The culture medium used for co-culture was EGM-2 cell culture medium with 0.5 μg / mL puromycin.
[0089] After obtaining a stable transfected CD34+ cell line through lentivirus transfection, the expression of VCAM-1scFv was quantified by flow cytometry, as shown in Figure 7.
[0090] The stability of VCAM-1scFv expression was detected, and the data showed that the expression of VCAM-1scFv was stable within three days, as shown in Figure 8.
[0091] VEGFA expression level analysis and Western blot analysis showed that, compared with PBS, CD34+PC transfected with lentiviral vector overexpressing CAR plasmid (LV-CAR) showed significantly increased VEGFA expression (all p<0.05), as shown in Figure 9.
[0092] VEGFA promotes the migration, differentiation, and proliferation of CD34+ progenitor cells. EdU assays showed that the LV-CAR group had significantly increased cell proliferation capacity compared to the other groups (all p < 0.05) (Figure 10). In freshly isolated CD34+ stem cells, flow cytometry analysis three days after CAR plasmid overexpression showed a significant increase in endothelial markers, including CD31 and VE-CAD (Figure 11).
[0093] The above results indicate that the chimeric antigen receptor-modified CD34+ stem cells prepared in this embodiment can be used to prepare products for the treatment of cardiovascular endothelial injury.
[0094] Those skilled in the art should understand that this application is not limited to the above embodiments. The embodiments and descriptions in the specification are merely illustrative of the principles of this application. Various changes and modifications can be made to this application without departing from the spirit and scope thereof, and all such changes and modifications fall within the scope of this application as claimed. The scope of protection of this application is defined by the appended claims and their equivalents.
Claims
1. A method for preparing chimeric antigen receptor-modified CD34+ stem cells, characterized in that, Includes the following steps: Step 1: Bone marrow fluid was flushed out from the femoral bone marrow of C57BL / 6J mice and purified by centrifugation to obtain purified C57BL / 6J mouse femoral bone marrow mononuclear cells; Step 2: The purified C57BL / 6J mouse femoral bone marrow mononuclear cells are separated and purified by magnetic bead separation to obtain CD34+ cells, which are then cultured, proliferated, and passaged to obtain C57BL / 6J mouse primary CD34+ stem cells. Step 3: Construct CAR overexpression plasmid; Step 4: Use the CAR overexpression plasmid and lentivirus to package and obtain a CAR overexpression lentiviral vector; Step 5: The CAR-overexpressing lentiviral vector is co-cultured with the primary CD34+ stem cells of C57BL / 6J mice to obtain chimeric antigen receptor-modified CD34+ stem cells.
2. The method for preparing chimeric antigen receptor-modified CD34+ stem cells according to claim 1, characterized in that: in, Step 1 includes: Femurs of C57BL / 6J mice were taken, and bone marrow cell suspension was washed out using M199 culture medium and filtered through a 70μm sieve to obtain the filtered bone marrow suspension.
3. The method for preparing chimeric antigen receptor-modified CD34+ stem cells according to claim 2, characterized in that: in, Step 1 also includes: The filtered bone marrow suspension was centrifuged at 37°C, 300 g / min, for 10 min. After resuspending the cells, the suspension was added above the lymphocyte separation medium and centrifuged at 18-20°C, 2000 r / min, for 30 min. The intermediate layer cells were collected, added to PBS buffer, centrifuged at 300 g / min, for 5 min, and resuspended to obtain purified C57BL / 6J mouse femoral bone marrow mononuclear cells.
4. The method for preparing chimeric antigen receptor-modified CD34+ stem cells according to claim 1, characterized in that: in, Step 2 includes: The purified C57BL / 6J mouse femoral bone marrow mononuclear cells were mixed with CD34+ magnetic beads and incubated at room temperature for 30 min to obtain a mixture.
5. The method for preparing chimeric antigen receptor-modified CD34+ stem cells according to claim 4, characterized in that: The magnetic beads used are MACS CD34 MicroBeads.
6. The method for preparing chimeric antigen receptor-modified CD34+ stem cells according to claim 4, characterized in that: in, Step 2 also includes: The mixture was sorted using a MACS magnetic sorting system to obtain a cell suspension, which was then transferred to a sorting tube. The sorted cells were washed multiple times to obtain enriched CD34+ stem cells.
7. The method for preparing chimeric antigen receptor-modified CD34+ stem cells according to claim 4, characterized in that: in, Step 2 also includes: The enriched CD34+ stem cells were resuspended in EGM-2 medium and the cell density was adjusted to 1×10⁻⁶. 6 The cell suspension was then transferred to a 6-well plate pre-coated with human plasma fibrin and cultured in a cell culture incubator at 37°C and 5% CO2. The medium was changed for the first time after 3 days, and the morphology and growth of the cells were observed.
8. The method for preparing chimeric antigen receptor-modified CD34+ stem cells according to claim 1, characterized in that: in, After obtaining the primary CD34+ stem cells of C57BL / 6J mice, it is necessary to perform immunophenotypic identification on the primary CD34+ stem cells of C57BL / 6J mice.
9. The method for preparing chimeric antigen receptor-modified CD34+ stem cells according to claim 8, characterized in that: The immunophenotypic identification was performed using flow cytometry and immunofluorescence, with the antibodies used being CD34 flow cytometry antibody and CD34 antibody, respectively.
10. The method for preparing chimeric antigen receptor-modified CD34+ stem cells according to claim 1, characterized in that: in, Step 3 includes: The scFv target VCAM-1, with CD28 as the hinge region and VEGFA as the intracellular domain. The VCAM-1 single-chain antibody and VEGFA gene were constructed into the PGMLV-EF1a-hinge_TM(CD28) vector to obtain the CAR overexpression plasmid.
11. The method for preparing chimeric antigen receptor-modified CD34+ stem cells according to claim 10, characterized in that: in, The nucleotide sequence of the scFv targeting VCAM-1 is shown in SEQ ID No:
1. The gene base sequence of VEGFA is shown in SEQ ID No:
2.
12. The method for preparing chimeric antigen receptor-modified CD34+ stem cells according to claim 1, characterized in that: in, In step 4, the lentivirus is derived from the supernatant of HEK293T cells.
13. The method for preparing chimeric antigen receptor-modified CD34+ stem cells according to claim 1, characterized in that: in, In step 4, the lentivirus packaging uses a kit to co-transfect 10 μL of the CAR overexpression plasmid with 10 μL of the lentivirus mixture and 60 μL of HGTransgene™ reagent for 2 days to obtain a virus concentrate, which is the CAR overexpression lentivirus vector.
14. The method for preparing chimeric antigen receptor-modified CD34+ stem cells according to claim 1, characterized in that: in, In step 5, the CAR-overexpressing lentiviral vector was diluted with 1×10⁻⁶ at an MOI of 50. 5 Primary CD34+ stem cells from C57BL / 6J mice were co-cultured for 16 hours to obtain chimeric antigen receptor-modified CD34+ stem cells. The culture medium used for co-culture was EGM-2 cell culture medium + 0.5 μg / mL puromycin.
15. A chimeric antigen receptor-modified CD34+ stem cell, characterized in that: It was prepared using the method for preparing chimeric antigen receptor-modified CD34+ stem cells as described in any one of claims 1-14.
16. The use of the chimeric antigen receptor-modified CD34+ stem cells as described in claim 15 in the preparation of products for the treatment of cardiovascular endothelial injury.
